Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Indian pharma giant Cipla released its Q4 FY 25 result, wherein it posted a healthy year-on-year growth of 30% in net profit ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share ...

Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

Cipla's CEO Umang Vohra asserts that the US mandate for lowering prescription drug costs will not affect Indian generic ...

Pharma giant Cipla announced a significant 30 percent increase in consolidated net profit attributable to shareholders for ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...